New York Blood Center, Inc.

The Applied Biosystems™ Axiom™ BloodGenomiX™ Array and Software provide a high-throughput solution for more precise blood matching research WALTHAM, Mass.--(BUSINESS WIRE)-- Thermo Fisher Scientific Inc., the world leader in serving science, today introduced the Applied Biosystems™ Axiom™ BloodGenomiX™ Array* and Software, a first-of-its-kind solution for more precise blood genotyping in clinical research. The new array detects most extended and rare blood groups, tissue (HLA) and platelet (HPA) types in a single, high-throughput assay, supporting future advancements in donor blood matching for extended phenotypes. Blood typing is a critical medical service used to match blood and tissue types ahead of transfusions and transplants. When an individual receives incompatible blood, they can form antibodies that can increase the risk of a severe, even life-threatening, reaction to future transfusions. This risk increases significantly for people who receive frequent transfusions, such as patients undergoing chemotherapy and people with inherited blood disorders such as sickle cell disorder. While testing for the four main blood types (A, B, AB, and O) and determining if the blood is Rh positive or negative is common practice, there are many more blood group systems, including some extremely rare blood types. Therefore, research is critical to bring extended blood typing into strategies to mitigate potential risks of hemolytic transfusion reactions in the future. “Adoption of DNA-based blood typing will pave the way for large-scale genomics research and the future establishment of international standards to improve the safety and efficacy of blood transfusion for millions of patients,” said Willem H Ouwehand, Blood transfusion Genomics Consortium chair and Professor of Experimental Haematology at the University of Cambridge and NHS Blood and Transplant in England. The Axiom BloodGenomiX Array covers more than 40 genes and 260 antigens across 38 blood group systems, in addition to HLA and HPA types. It was developed in collaboration with the Blood transfusion Genomics Consortium (BGC), an international partnership of blood services, research institutions and industry leaders that aims to improve the safety and efficacy of blood and platelet transfusion. In a validation study using 14,000 diverse DNA samples from the national blood services of Australia, Canada, England, Finland, the Netherlands, South Africa and the New York Blood Center, the array showed a high level of concordance (99.89%) with participants’ blood group antigen types. “The Blood transfusion Genomics Consortium’s goal is to develop an affordable, scalable blood typing solution that can one day be embedded in accredited labs globally,” said Dr. Connie Westhoff, BGC deputy chair and representing the National Center for Blood Group Genomics at the New York Blood Center. “Our vision is to one day make comprehensive blood typing for all donor and patient blood the standard of care.” For a complete workflow, the BloodGenomiX Array can be coupled with Applied Biosystems™ BloodGenomiX Reporter Software and the Applied Biosystems GeneTitan MC Instrument, helping to alleviate pain points with automated analysis, reporting and quality control. The workflow requires minimal hands-on time and can be run by existing lab staff. “The Axiom BloodGenomiX Array and Software provide a cost-effective, high-throughput solution for extended blood typing research,” said Kevin Lowitz, vice president and general manager, microarray solutions at Thermo Fisher Scientific. “In the future, having access to a scalable, array-based blood typing solution may help blood services effectively screen extended blood types for more precise blood matching.” For more information, please visit thermofisher.com/extendedbloodtyping and read the white paper, “Genotyping for extended and rare blood types.” *For research use only. Not for use in diagnostic procedures. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of more than $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit .

NEW YORK, May 1, 2024 /PRNewswire/ -- Traverse Biotech, Inc. has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH. This grant will support the development of our oral innate immunotherapy stimulant modality with an emphasis on the evaluation of monocytic cellular activation using pathogen-associated molecular patterns (PAMPs) motifs. Brandy Houser, co-Founder and CEO of Traverse Biotech, expressed: "We are grateful for the support of NIAID. We believe that our product candidate has broad applicability to several immunological pathologies where myeloid derived cells are dysfunctional and ultimately not effective in disease resolution." This work will be conducted in collaboration with Dr. Sara Lustigman, Head of Molecular Parasitology at Lindsley F. Kimball Research Institute of New York Blood Center Enterprises. Dr. Lustigman's extensive academic research in immunology and infectious diseases will enable the evaluation of Traverse's innate immune stimulator mechanism of action in validated preclinical pathogenic models. About Traverse Biotech, Inc. is a privately held US biotechnology company that develops innovative immunotherapy products. Traverse Biotech focuses on late-stage preclinical and early clinical development of product candidates derived from de-risked technology platforms. For each product within its pipeline, Traverse licenses worldwide commercialization rights from selected international biopharma companies that are divesting promising product candidates due to strategic portfolio rationalization. Via an original partnership model, Traverse Biotech accelerates therapeutic development of each asset through clinical proof-of-concept. Its flexible and lean operating structure enables rapid clinical evaluation and cost reduction around all aspects of product development reaching patients sooner. SOURCE Traverse Biotech

CLEVELAND, Feb. 13, 2024 /PRNewswire/ -- The National Cord Blood Network (NCBN) proudly announces its official launch, signaling a new era of advances and collaboration in cord blood transplantation. The NCBN aims to increase accessibility to life-saving cord blood transplantation for patients with hematologic malignancies in US Transplant Centers as well as optimize cord blood transplant practices. Led by internationally recognized adult and pediatric transplant specialists Dr. Juliet Barker, Director of the Weill Cornell Bone Marrow Transplant and Cellular Therapy Program at New York-Presbyterian and Weill Cornell Medicine, and Dr. Andromachi Scaradavou, Memorial Sloan Kettering Cancer Center, the NCBN brings together a consortium of transplant programs. The NCBN includes pioneering medical professionals in the cord blood field, and multiple collaborative partners, all united in a shared mission to enhance the utilization of cord blood transplantation across the United States. Marcie Finney, MBA, Cleveland Cord Blood Center, an experienced leader in healthcare administration, will serve as the Administrative Director of the National Cord Blood Network. Leveraging her extensive experience in managing complex healthcare initiatives, Finney will oversee the Network's operations, ensuring efficient execution of its mission and objectives. "We are thrilled to have created the National Cord Blood Network, a pivotal platform for driving transformative change in the field of cord blood transplant," stated Dr. Barker, Chair of the NCBN. "Through strategic collaborations and a shared vision, we aim to redefine the potential of cord blood-derived therapies and extend the reach of this life-saving treatment to many more patients. This will benefit patients with high-risk acute leukemias, those in need of urgent transplantation, and will address health disparities in the transplant field." Dr. Andromachi Scaradavou, Co-Chair of the NCBN, added, "The launch of the National Cord Blood Network marks a significant milestone in our collective effort to advance our understanding and application of cord blood transplantation. With a focus on inclusivity as well as cutting-edge research, we are committed to optimizing standards of care in graft selection and transplantation practices." The NCBN's comprehensive approach through multi-center collaborations will not only advance cord blood transplantation but will also increase the utilization of existing high-quality cord blood inventories all with the ultimate goal of establishing cord blood transplantation as a curative therapy for hematologic malignancies in Transplant Centers across the nation. The Network will collaborate with key national stakeholders to maximize the advancements in the field of alternative donor transplantation. The National Cord Blood Network was established with the generous support and funding provided by the Abraham J & Phyllis Katz Foundation. With a commitment to driving transformative advancements in cord blood transplantation and research, the Foundation's steadfast support has served as the cornerstone for the Network's pioneering initiatives. For more information about the National Cord Blood Network and its transformative initiatives, please visit . Contact Marcie Finney 440-554-4830 [email protected] SOURCE National Cord Blood Network